AUG 12, 2026 · PHASE 1 TRIAL
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
ClinicalTrials.gov
Phase 1 study registration with no reported results; evaluates safety and tolerability of a novel intrathecal agent in early-onset Alzheimer disease, requiring confirmation in later-phase trials.
Reported
Estimated enrollment60
Study phasePhase 1
Primary outcome measure (Part A)Frequency of Adverse Events, Up to 12 months